Biomarcadores moleculares en cáncer de mama

Breast cancer is a disease of high incidence in our country. To decide the best treatment, they are considered proteomic and histological prognostic factors. However, many times the therapy is inadequate; it remains necessary to identify new factors to optimize the diagnosis of disease including its...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Castro Guijarro, Ana Carla, Flamini, Marina Inés, Gómez, Laura Constanza, Redondo, Analía Lourdes, Sottile Fleury, Mayra Lis
Publicado:	2019
Materias:	Biología tumoral Biomarcadores Neoplasias de la Mama
Acceso en línea:	https://bdigital.uncu.edu.ar/fichas.php?idobjeto=14757

date_str_mv	2019-2021
todos_str_mv	80020180100926UN Biomarcadores moleculares en cáncer de mama Proyecto de investigación siip2019-2021 UNCuyoFCEN UNCuyoFCEN
disciplina_str_mv	Biología Ciencias médicas
descriptores_str_mv	Biología tumoral Biomarcadores Neoplasias de la Mama
titulo_str_mv	Biomarcadores moleculares en cáncer de mama Molecular biomarkers in breast cancer
description_str_mv	Breast cancer is a disease of high incidence in our country. To decide the best treatment, they are considered proteomic and histological prognostic factors. However, many times the therapy is inadequate; it remains necessary to identify new factors to optimize the diagnosis of disease including its biological aggressiveness and thus determine prognosis and appropriate treatment for the disease. It is also very important to find biomarkers to predict response and customize the antineoplastic treatment. For some years, our group studies the aberrant methylation profile of mammary carcinomas. The results suggest that this profile is specific and exclusive to malignant tumor tissues. In invasive ductal breast carcinomas we report the correlation between aberrant methylation of TP73 gene, the high expression of the deltaN-p73 isoform and a high histological grade, one of the key markers of poor prognosis. The TP73 protein has numerous isoforms that give rise to different biological functions and antagonistic. Not yet been studied whether they modify the sensitivity to conventional treatments used in breast tumors. The proposed objectives are: OBJECTIVE 1: In breast tumors with different clinical-pathological characteristics: a) Determine expression and cellular localization of TA-p73 and deltaN-p73 isoforms b) Correlate expression and localization of p73 isoforms with the tumor aggressiveness. OBJECTIVE 2: In mammary tumor cells with different molecular subtypes: a) Evaluate methylation of both TP73 gene promoters b) Evaluate expression and cellular localization of TA-p73 and deltaN-p73 isoforms. OBJECTIVE 3: Evaluate methylation of the TP73 gene in invasive ductal carcinomas of the breast of patients treated with doxorubicin. To develop the proposed objectives we will use tumor cell lines and human mammary tumor tissues. To determine expression and protein localization, immunohistochemistry and immunofluorescence studies and confocal microscopy will be performed, respectively. To study the methylation of genes, the pyrosequencing methodology will be used. El cáncer de mama es una enfermedad de elevada incidencia en nuestro país. Para decidir el mejor tratamiento, se consideran factores pronósticos histológicos y proteómicos. Sin embargo, en múltiples ocasiones la terapia resulta inadecuada, por lo que continúa siendo necesario identificar nuevos factores que permitan optimizar el diagnóstico de la enfermedad precisando su agresividad biológica y de esa manera determinar el pronóstico y tratamiento más adecuado para la enfermedad. También es muy importante encontrar biomarcadores que permitan predecir la respuesta y personalizar el tratamiento antineoplásico. Desde hace algunos años, nuestro grupo estudia el perfil de metilación aberrante de carcinomas mamarios. Los resultados obtenidos sugieren que este perfil es específico y exclusivo de tejidos tumorales malignos. En carcinomas ductales infiltrantes de mama reportamos la correlación entre la metilación aberrante del gen TP73, la elevada expresión de la isoforma deltaN-p73 y un alto grado histológico, uno de los principales marcadores de mal pronóstico. La proteína p73 posee numerosas isoformas que dan origen a funciones biológicas distintas y antagónicas. Aún no se ha estudiado si las mismas modifican la sensibilidad a los tratamientos de uso convencional en tumores mamarios. Los objetivos propuestos son: OBJETIVO 1: En tumores de mama con diferentes características clínico-patológicos: a) Estudiar la expresión y localización celular de las isoformas TA-p73 y deltaN-p73 b)correlacionar la expresión y localización de las isoformas con la agresividad tumoral. OBJETIVO 2: En células tumorales mamarias con distintos subtipos moleculares: a) Evaluar la metilación de ambos promotores del gen TP73 b) Evaluar la expresión y localización celular de las isoformas TA-p73 y deltaN-p73. OBJETIVO 3: Evaluar la metilación del gen TP73 en carcinomas ductales invasores de mama de pacientes tratadas con doxorrubicina. Para desarrollar los objetivos planteados utilizaremos líneas celulares tumorales y tejidos tumorales mamarios humanos. Para determinar expresión y localización proteica se realizarán estudios de inmunohistoquímica e inmunofluorescencia y microscopía confocal, respectivamente. Para estudiar la metilación de genes se empleará la metodología de pirosecuenciación.
autor_str_mv	Castro Guijarro, Ana Carla Flamini, Marina Inés Gómez, Laura Constanza Redondo, Analía Lourdes Sottile Fleury, Mayra Lis
object_type_str_mv	Textual: Investigación
dependencia_str_mv	Facultad de Ciencias Exactas y Naturales
id	14757
plantilla_str	Informe de Investigación
record_format	Informe de Investigación
tipo_str	textuales
type_str_mv	Articulos
title_full	Biomarcadores moleculares en cáncer de mama
title_fullStr	Biomarcadores moleculares en cáncer de mama Biomarcadores moleculares en cáncer de mama
title_full_unstemmed	Biomarcadores moleculares en cáncer de mama Biomarcadores moleculares en cáncer de mama
description	Breast cancer is a disease of high incidence in our country. To decide the best treatment, they are considered proteomic and histological prognostic factors. However, many times the therapy is inadequate; it remains necessary to identify new factors to optimize the diagnosis of disease including its biological aggressiveness and thus determine prognosis and appropriate treatment for the disease. It is also very important to find biomarkers to predict response and customize the antineoplastic treatment. For some years, our group studies the aberrant methylation profile of mammary carcinomas. The results suggest that this profile is specific and exclusive to malignant tumor tissues. In invasive ductal breast carcinomas we report the correlation between aberrant methylation of TP73 gene, the high expression of the deltaN-p73 isoform and a high histological grade, one of the key markers of poor prognosis. The TP73 protein has numerous isoforms that give rise to different biological functions and antagonistic. Not yet been studied whether they modify the sensitivity to conventional treatments used in breast tumors. The proposed objectives are: OBJECTIVE 1: In breast tumors with different clinical-pathological characteristics: a) Determine expression and cellular localization of TA-p73 and deltaN-p73 isoforms b) Correlate expression and localization of p73 isoforms with the tumor aggressiveness. OBJECTIVE 2: In mammary tumor cells with different molecular subtypes: a) Evaluate methylation of both TP73 gene promoters b) Evaluate expression and cellular localization of TA-p73 and deltaN-p73 isoforms. OBJECTIVE 3: Evaluate methylation of the TP73 gene in invasive ductal carcinomas of the breast of patients treated with doxorubicin. To develop the proposed objectives we will use tumor cell lines and human mammary tumor tissues. To determine expression and protein localization, immunohistochemistry and immunofluorescence studies and confocal microscopy will be performed, respectively. To study the methylation of genes, the pyrosequencing methodology will be used.
title	Biomarcadores moleculares en cáncer de mama
spellingShingle	Biomarcadores moleculares en cáncer de mama Biología tumoral Biomarcadores Neoplasias de la Mama Castro Guijarro, Ana Carla Flamini, Marina Inés Gómez, Laura Constanza Redondo, Analía Lourdes Sottile Fleury, Mayra Lis
topic	Biología tumoral Biomarcadores Neoplasias de la Mama
topic_facet	Biología tumoral Biomarcadores Neoplasias de la Mama
publishDate	2019
author	Castro Guijarro, Ana Carla Flamini, Marina Inés Gómez, Laura Constanza Redondo, Analía Lourdes Sottile Fleury, Mayra Lis
author_facet	Castro Guijarro, Ana Carla Flamini, Marina Inés Gómez, Laura Constanza Redondo, Analía Lourdes Sottile Fleury, Mayra Lis
tags_str_mv	siip2019-2021
title_sort	Biomarcadores moleculares en cáncer de mama
title_short	Biomarcadores moleculares en cáncer de mama
url	https://bdigital.uncu.edu.ar/fichas.php?idobjeto=14757
estado_str	3
building	Biblioteca Digital
filtrotop_str	Biblioteca Digital
collection	Informe de Investigación
institution	Sistema Integrado de Documentación
indexed_str	2023-04-25 00:35
_version_	1764120125167894528

Biomarcadores moleculares en cáncer de mama

Ejemplares similares